Our Innovative Projects
PDX/O Oncology Platform
InnoSer has many collaborative projects with research groups from both academia and industry settings to develop novel technologies for use in preclinical settings. This includes a project executed in partnership with Vrije Universiteit Brussel and in close collaboration with Jessa Hospital in Hasselt, Belgium, and Leiden University Medical Center (LUMC, the Netherlands) that resulted in the development of an integrated PDXO drug screening platform. This platform consists of two complementary components, patient-derived xenografts (PDX) and patient-derived organoids (PDO), which are characterized in the same manner. Such models resemble the original patient-derived tumour both phenotypically and genetically. For this reason, one of the main advantages of such a platform is its predictive value in drug screening, as your compounds can be coherently tested both in vitro and in vivo, using the same starting parental material.
Many xenografts, organoids or combined models are already validated and currently available for compound testing. For other models, we are happy to collaborate and validate the platform with your compounds.
Want to read more?
STXBP1 Foundation and InnoSer validate R122X, a patient-variant mouse model of STXBP1 encephalopathy, to help expand therapeutic opportunities in STXBP1 research
Gene therapies, antisense oligonucleotides (ASOs), RNA editing technologies, and other precision medicine approaches are rapidly transforming the therapeutic landscape for STXBP1 encephalopathy. Currently, around 16 candidate therapies are in development across five...
![Cognitive profiling in the APP[V717I]xTau[P301S] mouse model](https://www.innoserlaboratories.com/wp-content/uploads/2026/07/Figure-1-MWM.png)
Cognitive profiling in the APP[V717I]xTau[P301S] mouse model
In this month's update, we revisit the APP[V717I]xTau[P301S] model with newly in-house generated Morris Water Maze (MWM) data, reconfirming the spatial memory deficits previously described for this model and reinforcing the translational value of the model.The...
Total kidney volume (TKV) as a translationally relevant, non-invasive disease progression readout
In this month's newsletter, we invite you to explore how InnoSer's longitudinal total kidney volume (TKV) assessment via non-invasive ultrasound imaging in our ADPKD mouse model provides a clinically aligned structural readout that directly supports decision-making in...